Plasma Tau Variants Detected by a Novel Anti-Tau Monoclonal Antibody: A Potential Biomarker for Alzheimer’s Disease

González, Alina Alerm; Guzmán‐Martínez, Leonardo; Maccioni, Ricardo B.

doi:10.3233/jad-200386

Cited by 4 publications

(3 citation statements)

References 33 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Knowing the specific molecular processing will guide us to find biomarkers that can be monitored in less invasive tissues such as cerebrospinal fluid or plasma. For example, the detection of tau phosphorylated in plasma has already been reported [ 28 , 29 ]. Therefore, the use of computational technology such as convolutional neural networks to study this type of post-mortem imaging is very relevant and can provide significant value in the search for specific biomarkers for each group of neurodegenerative diseases, with the aim of implementing an early diagnosis in patients.…”

Section: Discussionmentioning

confidence: 99%

A Novel Automatic Quantification Protocol for Biomarkers of Tauopathies in the Hippocampus and Entorhinal Cortex of Post-Mortem Samples Using an Extended Semi-Siamese U-Net

Campero-García

Cantoral-Ceballos

Martínez-Maldonado

et al. 2022

Biology

View full text Add to dashboard Cite

Efforts have been made to diagnose and predict the course of different neurodegenerative diseases through various imaging techniques. Particularly tauopathies, where the tau polypeptide is a key participant in molecular pathogenesis, have significantly increased their morbidity and mortality in the human population over the years. However, the standard approach to exploring the phenomenon of neurodegeneration in tauopathies has not been directed at understanding the molecular mechanism that causes the aberrant polymeric and fibrillar behavior of the tau protein, which forms neurofibrillary tangles that replace neuronal populations in the hippocampal and cortical regions. The main objective of this work is to implement a novel quantification protocol for different biomarkers based on pathological post-translational modifications undergone by tau in the brains of patients with tauopathies. The quantification protocol consists of an adaptation of the U-Net neural network architecture. We used the resulting segmentation masks for the quantification of combined fluorescent signals of the different molecular changes tau underwent in neurofibrillary tangles. The quantification considers the neurofibrillary tangles as an individual study structure separated from the rest of the quadrant present in the images. This allows us to detect unconventional interaction signals between the different biomarkers. Our algorithm provides information that will be fundamental to understanding the pathogenesis of dementias with another computational analysis approach in subsequent studies.

show abstract

Section: Discussionmentioning

confidence: 99%

A Novel Automatic Quantification Protocol for Biomarkers of Tauopathies in the Hippocampus and Entorhinal Cortex of Post-Mortem Samples Using an Extended Semi-Siamese U-Net

Campero-García

Cantoral-Ceballos

Martínez-Maldonado

et al. 2022

Biology

View full text Add to dashboard Cite

show abstract

“…Diagnosis in the preclinical stage requires the absence of clinical signs and symptoms of AD and the presence of at least one biomarker of AD, which often requires early biomarkers for diagnosis [51,52]. Long-term clinical cohort studies have documented the importance of platelet Tau variants as early diagnosis or the prevention of neurodegenerative diseases including AD [53,54], which is consistent with relevant results, indicating that phosphorylated Tau in plasma may be an essential biomarker in the early stage of AD [55,56]. Mild cognitive impairment and AD are assessed according to the severity of cognitive impairment.…”

Section: Inflammation and Admentioning

confidence: 99%

Exercise suppresses neuroinflammation for alleviating Alzheimer’s disease

Wang

Zhang

Liang

et al. 2023

J Neuroinflammation

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a chronic neurodegenerative disease, with the characteristics of neurofibrillary tangle (NFT) and senile plaque (SP) formation. Although great progresses have been made in clinical trials based on relevant hypotheses, these studies are also accompanied by the emergence of toxic and side effects, and it is an urgent task to explore the underlying mechanisms for the benefits to prevent and treat AD. Herein, based on animal experiments and a few clinical trials, neuroinflammation in AD is characterized by long-term activation of pro-inflammatory microglia and the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasomes. Damaged signals from the periphery and within the brain continuously activate microglia, thus resulting in a constant source of inflammatory responses. The long-term chronic inflammatory response also exacerbates endoplasmic reticulum oxidative stress in microglia, which triggers microglia-dependent immune responses, ultimately leading to the occurrence and deterioration of AD. In this review, we systematically summarized and sorted out that exercise ameliorates AD by directly and indirectly regulating immune response of the central nervous system and promoting hippocampal neurogenesis to provide a new direction for exploring the neuroinflammation activity in AD.

show abstract

“…Se postula que este nuevo biomarcador en plasma sería una herramienta para utilizar en conjunto con Alz-tau® y así lograr un diagnóstico más certero utilizando los dos tipos de muestra (plasma y plaquetas). Con estos antecedentes los autores proponen que ambos biomarcadores serían de utilidad en el diagnóstico de la etapa preclínica de la EA (González et al, 2020).…”

Section: Arriagada and áLvarezunclassified

Proteína tau como biomarcador en Alzheimer preclínico

Arriagada

Villalobos²

2022

ARS med

View full text Add to dashboard Cite

El desarrollo de biomarcadores de la proteína tau para el diagnóstico temprano de la enfermedad de Alzheimer (EA) emerge como un desafío fundamental, pudiendo mejorar la efectividad de un tratamiento preventivo o que enlentezca la progresión de la enfermedad. Esta revisión analiza las evidencias que justificarían el uso de la proteína tau como biomarcador en Alzheimer preclínico. Para esto se seleccionaron artículos científicos (2011-2021) que incluyeran a la proteína tau en plasma y plaquetas como biomarcador. La presencia de la proteína tau fosforilada en el líquido cefalorraquídeo presenta limitaciones por su carácter invasivo mientras que las técnicas de imagen son costosas. La medición de tau en plaquetas se correlaciona con la severidad de la demencia, y sería útil en el seguimiento de la EA. Sin embargo, la pertinencia de su uso en la detección temprana de EA se mantiene en discusión. La presencia de proteína tau fosforilada en plasma correspondería al biomarcador con mayor nivel de desarrollo, respecto de beta amiloide. La proteína tau plasmática detecta la EA con gran precisión en casos de demencia y ha sido validada por estudios neuropatológicos. p-tau217 plasmática medida por primera vez junto a técnicas de imagen, fue importante en la etapa preclínica de EA pudiendo predecir la formación de ovillos neurofibrilares. La correlación entre especies fosforiladas de tau en plasma y EA preclínica ha sido bien establecida, por lo que su uso como biomarcador podría ser de utilidad para la comprensión del proceso fisiopatológico de la neurodegeneración y la detección temprana de EA.

show abstract

Plasma Tau Variants Detected by a Novel Anti-Tau Monoclonal Antibody: A Potential Biomarker for Alzheimer’s Disease

Cited by 4 publications

References 33 publications

A Novel Automatic Quantification Protocol for Biomarkers of Tauopathies in the Hippocampus and Entorhinal Cortex of Post-Mortem Samples Using an Extended Semi-Siamese U-Net

A Novel Automatic Quantification Protocol for Biomarkers of Tauopathies in the Hippocampus and Entorhinal Cortex of Post-Mortem Samples Using an Extended Semi-Siamese U-Net

Exercise suppresses neuroinflammation for alleviating Alzheimer’s disease

Proteína tau como biomarcador en Alzheimer preclínico

Contact Info

Product

Resources

About